A breakthrough in solving microbial resistance: Harvard develops a broad-spectrum anti-infective vaccine supported by dual technologies

Article source: Medical Rubik's Cube Pro

Author: Bai Lu

With the increasing number of drug-resistant microbial infections, the outbreak of pathogenic bacteria and the new biological threats that may emerge in the future, clinical interventions for infectious diseases are facing more and more challenges

In response to this challenge, a multidisciplinary research team from the Wyss Institute for Biological Inspired Engineering (Wyss Institute for Biological Inspired Engineering) and John A.

ciVAX's strong immunogenicity, low incidence of adverse events, and modular production process make it a potentially powerful tool to deal with bacterial epidemics and biological threats

With dual technology support, the new vaccine not only has a broad antibacterial spectrum, but also can be quickly assembled and used

The article’s first author, Dr.

The second technical component of ciVAX is the vaccine technology based on biological materials

In order to assemble the ciVAX vaccine, the research team used FcMBL-coated magnetic microspheres to capture the carbohydrate-containing surface molecules of the inactivated bacteria (called pathogen-associated molecular patterns (PAMP)), and then combined the complex with mesoporous silica (MPS).

After subcutaneous injection in mice, MPS forms a permeable and biodegradable scaffold that can recruit and reprogram the immature dendritic cells (DC) of the immune system to present the captured PAMP-derived antigens, and Activate and release them again

Production and application of ciVax infection vaccine against pathogenic E.

The research team found that the ciVAX vaccine can rapidly enhance the accumulation and activation of DC at the injection site, and increase the number of different types of T cells in DC, antibody-producing B cells, and draining lymph nodes, thereby generating an effective pathogen-directed immune response

The technology is modular and very suitable for the production of ciVAX for new pathogens.

Significant results in animal experiments, great potential for new vaccines

In order to explore the potential of this technology, the researchers conducted a series of animal experiments

Source: Nature Biomedical Engineering

In pig models of septic shock induced by different human E.

Source: Nature Biomedical Engineering

Finally, using a method of simulating a "circular" vaccination protocol in human or animal populations, when the ciVax vaccine is loaded with pathogen-derived material isolated from an animal infected with a lethal E.

CiVAX produced from animals infected with E.

Note: The original text has been deleted

Reference materials:

1# Biomaterial vaccines ward off broad range of bacterial infections and septic shock (Source: Wyss Institute for Biological Inspired Engineering official website)

2# Michael Super et al.